Insider · CIK 0001817012
Dennis Matheis
Files at DRIO (DarioHealth Corp.), LUCD (Lucid Diagnostics Inc.). First filing May 22, 2025, latest May 21, 2026.
Dennis Matheis files SEC Form 4 as director at LUCD (Lucid Diagnostics Inc.), and also at DRIO (DarioHealth Corp.). Since May 22, 2025, Dennis Matheis has reported 4 open-market buys worth $1.3M and 0 open-market sells worth $0, the latest filed on May 21, 2026.
After Dennis Matheis's past buys, the stock trailed the S&P 500 by a median 35.9% over six months (n = 3), and 33% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $245k of LUCD on May 20, 2026, filed May 21, 2026, scored 52 (moderate). In the last 12 months: 1 buy worth $245k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LUCD: Lucid Diagnostics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 52Moderate | LUCDbuy Lucid Diagnostics Inc. | $245k 245,000 shares | +31% | +6% from low-37% from high | |
| 28Weak | LUCDbuy Lucid Diagnostics Inc. | $102k 100,000 shares | +18% | - | |
| 42Moderate | LUCDbuy Lucid Diagnostics Inc. | $458k 350,000 shares | +162% | - | |
| 40Moderate | LUCDbuy Lucid Diagnostics Inc. | $458k 350,000 shares | - | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | DRIO DarioHealth Corp. | AGrant or award Common Stock | +44,000 | $0.00 | $0 | 87,026 | 15 d ago |
| May 20, 2026 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +245,000 | $1.00 | $245k | 1,033,443 | May 21, 2026 |
| Feb 20, 2026 | LUCD Lucid Diagnostics Inc. | AGrant or award Common Stock | +123,000 | $0.00 | $0 | 788,443 | Feb 24, 2026 |
| Sep 11, 2025 | DRIO DarioHealth Corp. | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 27,631 | Sep 15, 2025 |
| Aug 20, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +100,000 | $1.02 | $102k | 665,443 | Aug 22, 2025 |
| May 20, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +187,098 | $1.30 | $242k | 402,541 | May 23, 2025 |
| May 21, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +129,684 | $1.32 | $172k | 532,225 | May 23, 2025 |
| May 22, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +33,218 | $1.32 | $44k | 565,443 | May 23, 2025 |
| May 20, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +187,098 | $1.30 | $242k | 187,098 | May 22, 2025 |
| May 21, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +129,684 | $1.32 | $172k | 316,782 | May 22, 2025 |
| May 22, 2025 | LUCD Lucid Diagnostics Inc. | POpen-market purchase Common Stock | +33,218 | $1.32 | $44k | 350,000 | May 22, 2025 |
Questions about Dennis Matheis
Answered from the filings on this page, as of the latest one.
Is Dennis Matheis buying or selling?
In the last 12 months Dennis Matheis reported 1 open-market buy worth $245k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $245k of LUCD on May 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Dennis Matheis's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 35.9% over six months across 3 past buys, with 33% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Dennis Matheis file Form 4?
Dennis Matheis has filed Form 4 at LUCD (Lucid Diagnostics Inc.); DRIO (DarioHealth Corp.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.